Lenovo Commits to Hiring 12,000 R&D Professionals, and Outlines Vision to Achieve Net-zero by 2050
4.4.2022 09:00:00 EEST | Business Wire | Press release
Today, at Lenovo’s annual company kick-off to mark the start of Lenovo’s financial year, Chairman and CEO, Yuanqing Yang, set out the company’s bold vision for the year ahead. This includes building on its recent commitment to double investment in Research and Development (R&D) and announcing that the Group will hire 12,000 R&D professionals around the world over the next three years, as well as setting a vision to achieve net-zero by 2050*. The intensified commitment to innovation, underpinned by Environmental, Social, Governance (ESG) commitments, comes as Lenovo continues its transformation from a devices company to a global technology powerhouse that also includes services and solutions.
Lenovo’s CEO outlined the Group’s mission for the year ahead to build new growth engines, invest in new and emerging technologies, and continue driving sustainable profitability improvements.
R&D remains a crucial priority for Lenovo in fiscal year 22/23. R&D investment will be doubled, and 12,000 new R&D professionals hired over the next three years, in addition to around 5,000 brought into the company during fiscal FY21/22, to support research across the new IT architecture of ‘Client-Edge-Cloud-Network-Intelligence’
“My vision for Lenovo’s innovation is to become one of the world’s leading ICT companies, a pioneer and enabler of intelligent transformation,” said Chairman and CEO, Yuanqing Yang. “Our investment plan will center around the 'Client-Edge-Cloud-Network-Intelligence' architecture, with a three-track approach to focus on short-, medium- and long-term payback. Our intention is to optimize between technology with quick market returns and foundational research, and between continuous improvement and breakthrough innovation.”
R&D efforts will focus around the new and emerging IT architecture. Teams will work on new product and business model innovation, incubating technologies from edge computing to technology which will help businesses capitalize on the metaverse, and emerging and disruptive innovation like next-generation AI and heterogeneous computing to help them prepare for the future. All with the intention of helping businesses of all sizes capitalize on new and emerging technologies like the metaverse.
Alongside its R&D commitments, Lenovo outlined its vision to become net-zero by 2050, and Lenovo is working with the Science Based Target Initiative to establish goals that support this vision. The company has been reporting on its ESG commitments for the past 14 years, including outlining its work and goals around climate change mitigation, the circular economy, and sustainable materials. In 2020, Lenovo exceeded its 2020 emission reduction goals a year ahead of schedule and has already established science-based targets for 2030
In addition to the net-zero vision, Yuanqing Yang further committed to positively impacting 15 million lives through philanthropic programs and partnerships by 2025. The company’s philanthropic mission provides smarter technology for all by empowering underrepresented communities with access to technology and STEM education.
Yuanqing Yang concluded: “Lenovo is much more than business growth and financial success. We are innovators who are committed to helping solve humanity’s greatest challenges. Smarter powers what’s next.”
Read more about Lenovo’s sustainability initiatives in the most recent ESG Report, including the 2030 greenhouse gas emissions reduction goals approved by the Science-Based Targets initiative.
* Lenovo is working with the Science Based Target Initiative to establish goals that support this vision.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services, and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220403005029/en/
Contact information
Stuart Gill, sgill@lenovo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom